HSCS logo

Heart Test Laboratories (HSCS) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

16 June 2022

Indexes:

Not included

Description:

HSCS (Heart Test Laboratories) specializes in advanced heart health testing. They provide innovative diagnostic services to help identify heart conditions early. Their goal is to improve patient outcomes through accurate testing and personalized care, making heart health accessible and understandable for everyone.

Key Details

Price

$3.58

Annual Revenue

$18.60 K(+257.69% YoY)

Annual EPS

-$19.00(+76.25% YoY)

Annual ROE

-175.02%

Beta

0.87

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 17, 2024

Analyst ratings

Recent major analysts updates

18 Dec '24 Maxim Group
Buy
23 Sept '24 Ascendiant Capital
Buy
30 Jan '23 Ascendiant Capital
Buy
19 Dec '22 Maxim Group
Buy
09 Nov '22 Maxim Group
Buy
08 Aug '22 Benchmark
Speculative Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
HSCS
globenewswire.com16 December 2024

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update.

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
HSCS
https://www.globenewswire.com/news-release/2024/10/14/2962846/0/en/HeartSciences-to-Participate-in-the-2024-Maxim-Healthcare-Virtual-Summit.html14 October 2024

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024.

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
HSCS
globenewswire.com12 September 2024

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
HSCS
globenewswire.com12 September 2024

Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the close of a non-dilutive financing, with $1.9 million in net proceeds.  The unsecured loan note has an 18-month maturity date and follows the recent 12-month extension of a $500,000 loan note to September 2025.

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
HSCS
globenewswire.com29 July 2024

Southlake, TX, July 29, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the fiscal year 2024 ended April 30, 2024 and provided a business update.

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
HSCS
globenewswire.com11 July 2024

Southlake, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that intellectual property (IP) exclusively licensed to HeartSciences has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for the detection of left ventricular (LV) and/or right ventricular (RV) dysfunction using deep learning, further strengthening the Company's AI-ECG IP portfolio. Heart failure (HF) is a growing worldwide public health issue affecting 64 million people annually1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
HSCS
globenewswire.com20 May 2024

Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO). To date, HeartSciences has been granted nine US patents and 35 international patents for a total of 44 granted patents.

Why Is Heart Test Laboratories (HSCS) Stock Down 21% Today?
Why Is Heart Test Laboratories (HSCS) Stock Down 21% Today?
Why Is Heart Test Laboratories (HSCS) Stock Down 21% Today?
HSCS
InvestorPlace06 March 2024

Heart Test Laboratories (NASDAQ: HSCS ) stock is falling hard on Wednesday after the medical technology company announced a secondary offering for its shares. Heart Test Laboratories notes that this is a resale of 34,684,859 shares of HSCS stock by a few shareholders.

Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?
Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?
Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?
HSCS
InvestorPlace15 November 2023

Heart Test Laboratories (NASDAQ: HSCS ) stock is rising higher on Wednesday without any clear news from the maker of cardiovascular diagnostic devices. There have been no new press releases or filings with the Securities and Exchange Commission that explain why HSCS stock is rising higher today.

Why Is Heart Test Laboratories (HSCS) Stock Moving Today?
Why Is Heart Test Laboratories (HSCS) Stock Moving Today?
Why Is Heart Test Laboratories (HSCS) Stock Moving Today?
HSCS
InvestorPlace21 September 2023

Heart Test Laboratories (NASDAQ: HSCS ) stock is on the move Thursday after announcing an agreement with the Icahn School of Medicine at Mount Sinai. This new agreement has Heart Test Laboratories' HeartSciences working with Icahn Mount Sinai to commercialize electrocardiographic artificial intelligence ( AI ) algorithms and assets.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Heart Test Laboratories?
  • What is the ticker symbol for Heart Test Laboratories?
  • Does Heart Test Laboratories pay dividends?
  • What sector is Heart Test Laboratories in?
  • What industry is Heart Test Laboratories in?
  • What country is Heart Test Laboratories based in?
  • When did Heart Test Laboratories go public?
  • Is Heart Test Laboratories in the S&P 500?
  • Is Heart Test Laboratories in the NASDAQ 100?
  • Is Heart Test Laboratories in the Dow Jones?
  • When does Heart Test Laboratories report earnings?
  • Should I buy Heart Test Laboratories stock now?

What is the primary business of Heart Test Laboratories?

HSCS (Heart Test Laboratories) specializes in advanced heart health testing. They provide innovative diagnostic services to help identify heart conditions early. Their goal is to improve patient outcomes through accurate testing and personalized care, making heart health accessible and understandable for everyone.

What is the ticker symbol for Heart Test Laboratories?

The ticker symbol for Heart Test Laboratories is NASDAQ:HSCS

Does Heart Test Laboratories pay dividends?

No, Heart Test Laboratories does not pay dividends

What sector is Heart Test Laboratories in?

Heart Test Laboratories is in the Healthcare sector

What industry is Heart Test Laboratories in?

Heart Test Laboratories is in the Medical Devices industry

What country is Heart Test Laboratories based in?

Heart Test Laboratories is headquartered in United States

When did Heart Test Laboratories go public?

Heart Test Laboratories's initial public offering (IPO) was on 16 June 2022

Is Heart Test Laboratories in the S&P 500?

No, Heart Test Laboratories is not included in the S&P 500 index

Is Heart Test Laboratories in the NASDAQ 100?

No, Heart Test Laboratories is not included in the NASDAQ 100 index

Is Heart Test Laboratories in the Dow Jones?

No, Heart Test Laboratories is not included in the Dow Jones index

When does Heart Test Laboratories report earnings?

The date for Heart Test Laboratories's next earnings report has not been announced yet

Should I buy Heart Test Laboratories stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions